These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 15837982)

  • 21. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
    Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
    Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor shrinkage evaluation during and after preoperative doxorubicin and cyclophosphamide followed by docetaxel in patients with breast cancer.
    Puglisi F; Mansutti M; Aprile G; Minisini AM; Di Loreto C; Bazzocchi M; Londero V; Cedolini C; Gentile G; Pizzolitto S; Piga A; Sobrero A
    Anticancer Res; 2004; 24(4):2487-93. PubMed ID: 15330203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group].
    von Minckwitz G; Raab G; Schütte M; Hilfrich J; Blohmer JU; Gerber B; Costa SD; Merkle E; Eidtmann H; Lampe D; Jackisch C; du Bois A; Tulusan AH; Gademann G; Sinn HP; Caputo A; Graf E; Kaufmann M
    Zentralbl Gynakol; 2001 Sep; 123(9):497-504. PubMed ID: 11709742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
    von Minckwitz G; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; Untch M
    J Clin Oncol; 2010 Apr; 28(12):2015-23. PubMed ID: 20308671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).
    Linden HM; Haskell CM; Green SJ; Osborne CK; Sledge GW; Shapiro CL; Ingle JN; Lew D; Hutchins LF; Livingston RB; Martino S
    J Clin Oncol; 2007 Feb; 25(6):656-61. PubMed ID: 17308269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099.
    Alvarez RH; Booser DJ; Cristofanilli M; Sahin AA; Strom EA; Guerra L; Kau SW; Gonzalez-Angulo AM; Hortobagyi GN; Valero V
    Cancer; 2010 Mar; 116(5):1210-7. PubMed ID: 20082452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.
    Burstein HJ; Parker LM; Keshaviah A; Doherty J; Partridge AH; Schapira L; Ryan PD; Younger J; Harris LN; Moy B; Come SE; Schumer ST; Bunnell CA; Haldoupis M; Gelman R; Winer EP
    J Clin Oncol; 2005 Nov; 23(33):8340-7. PubMed ID: 16293865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer.
    Vriens BE; Aarts MJ; de Vries B; van Gastel SM; Wals J; Smilde TJ; van Warmerdam LJ; de Boer M; van Spronsen DJ; Borm GF; Tjan-Heijnen VC;
    Eur J Cancer; 2013 Oct; 49(15):3102-10. PubMed ID: 23850450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.
    Schneeweiss A; Marmé F; Ruiz A; Manikhas AG; Bottini A; Wolf M; Sinn HP; Mansouri K; Kennedy L; Bauknecht T
    Ann Oncol; 2011 Mar; 22(3):609-617. PubMed ID: 20732932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Toxicity of doxorubicin and cyclophosphamide (60 mg/600 mg/m2) in adjuvant chemotherapy for breast cancer].
    Tsutani Y; Saeki T; Aogi K; Ohsumi S; Takashima S
    Gan To Kagaku Ryoho; 2005 Jun; 32(6):809-13. PubMed ID: 15984521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer.
    Yardley DA; Burris HA; Farley CP; Barton JH; Peacock NW; Spigel DR; Greco FA; Hainsworth JD
    Clin Breast Cancer; 2008 Jun; 8(3):242-8. PubMed ID: 18650154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pilot study of dose intense doxorubicin and cyclophosphamide followed by infusional paclitaxel in high-risk primary breast cancer.
    Zujewski JA; Eng-Wong J; O'Shaughnessy J; Venzon D; Chow C; Danforth D; Kohler DR; Cusack G; Riseberg D; Cowan KH
    Breast Cancer Res Treat; 2003 Sep; 81(1):41-51. PubMed ID: 14531496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
    Bear HD; Anderson S; Smith RE; Geyer CE; Mamounas EP; Fisher B; Brown AM; Robidoux A; Margolese R; Kahlenberg MS; Paik S; Soran A; Wickerham DL; Wolmark N
    J Clin Oncol; 2006 May; 24(13):2019-27. PubMed ID: 16606972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study.
    Cardoso F; Ferreira Filho AF; Crown J; Dolci S; Paesmans M; Riva A; Di Leo A; Piccart MJ
    Anticancer Res; 2001; 21(1B):789-95. PubMed ID: 11299845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.
    Coombes RC; Bliss JM; Espie M; Erdkamp F; Wals J; Tres A; Marty M; Coleman RE; Tubiana-Mathieu N; den Boer MO; Wardley A; Kilburn LS; Cooper D; Thomas MW; Reise JA; Wilkinson K; Hupperets P
    J Clin Oncol; 2011 Aug; 29(24):3247-54. PubMed ID: 21768453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer.
    Loesch D; Greco FA; Senzer NN; Burris HA; Hainsworth JD; Jones S; Vukelja SJ; Sandbach J; Holmes F; Sedlacek S; Pippen J; Lindquist D; McIntyre K; Blum JL; Modiano MR; Boehm KA; Zhan F; Asmar L; Robert N
    J Clin Oncol; 2010 Jun; 28(18):2958-65. PubMed ID: 20479419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer.
    Lee KS; Ro J; Nam BH; Lee ES; Kwon Y; Kwon HS; Chung KW; Kang HS; Kim EA; Kim SW; Shin KH; Kim SK
    Breast Cancer Res Treat; 2008 Jun; 109(3):481-9. PubMed ID: 17653851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II study of primary dose-dense sequential doxorubicin plus cyclophosphamide and docetaxel in cT4 breast cancer.
    Torrisi R; Orlando L; Ghisini R; Veronesi P; Intra M; Rocca A; Balduzzi A; Cardillo A; Goldhirsch A; Colleoni M
    Anticancer Res; 2006; 26(5B):3861-4. PubMed ID: 17094414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of docetaxel, doxorubicin, and infusional 5-fluorouracil in the treatment of patients with locally advanced breast cancer.
    Thatai LC; Vishnubhotla P; Biernat L; Flaherty L; LoRusso P; Simon M; Stephens D; Vereeke K; Abrams J; Bouwman D; Philip PA
    Am J Clin Oncol; 2006 Oct; 29(5):484-9. PubMed ID: 17023784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.